Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VNDA stock price vs MGA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MGA's multiple
Needs MGA P/S.
Implied fair value · at VNDA's multiple
Needs Revenue / share.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VNDA FY 2025 (ended Dec 31, 2025) · MGA FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 81% equity / 19% debt · EV / Revenue 1.49x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Magna International Inc. · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.24x
0.38x
Net debt / EBITDA
Leverage against operating earnings
0.05x
0.96x
Cash and equivalents
Liquid reserves on the balance sheet
$84.85M
$1.61B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
VNDA vs SUPN
CATALYST PHARMACEUTICALS, INC.
VNDA vs CPRX
Harmony Biosciences Holdings, Inc.
VNDA vs HRMY
ELI LILLY & Co
VNDA vs LLY
INCYTE CORP
VNDA vs INCY
Sarepta Therapeutics, Inc.
VNDA vs SRPT
Adient plc
VNDA vs ADNT
AMERICAN AXLE & MANUFACTURING HOLDINGS INC
VNDA vs AXL
DANA INC
VNDA vs DAN
BORGWARNER INC
VNDA vs BWA
$78.23M
$4.74B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
